CD274 and non-small cell lung carcinoma: Based on the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), PD-L1 expression no less than 50% on TC or 10% on IC was defined as high expression, which implies that immunotherapy could be a first-line treatment for advanced NSCLC (8, 9).